A European, multicentre, retrospective, non‐interventional study (EU‐TREAT) of the effectiveness of insulin degludec after switching basal insulin in a population with type 1 or type 2 diabetes

Ítems similars

• Clinical benefits of switching to insulin degludec irrespective of previous basal insulin therapy in people with Type 1 or Type 2 diabetes: evidence from a European, multicentre, retrospective, non‐interventional study (EU‐TREAT)
  per: Knudsen, S. T., et al.
  Publicat: (2019)
• Switching “Real-World” Diabetes Patients to Degludec from Other Basal Insulins Provides Different Clinical Benefits According to Their Baseline Glycemic Control
  per: Tentolouris, Nikolaos, et al.
  Publicat: (2019)
• Use and effectiveness of a fixed‐ratio combination of insulin degludec/liraglutide (IDegLira) in a real‐world population with type 2 diabetes: Results from a European, multicentre, retrospective chart review study
  per: Price, Hermione, et al.
  Publicat: (2018)
• Insulin degludec U100 is associated with lower risk for severe and symptomatic hypoglycemia as compared with insulin glargine U100 in subjects with type 1 diabetes
  per: Tentolouris, Anastasios, et al.
  Publicat: (2018)
• Fixed‐ratio combination of insulin degludec and liraglutide (IDegLira) improves cardiovascular risk markers in patients with type 2 diabetes uncontrolled on basal insulin
  per: Vilsbøll, Tina, et al.
  Publicat: (2019)